{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:14Z","timestamp":1792784954310,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ALX Oncology","id":[{"id":"https:\/\/ror.org\/05bw1xb15","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04700-3","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:02:10Z","timestamp":1790240530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7142-1246","authenticated-orcid":false,"given":"Zev","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-6957","authenticated-orcid":false,"given":"Cl\u00e9lia","family":"Coutzac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"De La Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-6165","authenticated-orcid":false,"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-4531","authenticated-orcid":false,"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Forgie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherry","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9993-0116","authenticated-orcid":false,"given":"Daniel","family":"Brickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios C.","family":"Tsiatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-703X","authenticated-orcid":false,"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"4700_CR1","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662\u20136667 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4700_CR2","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","volume":"23","author":"PS Petrova","year":"2017","unstructured":"Petrova, P. S. et al. TTI-621 (SIRP\u03b1Fc): A CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin. Cancer Res. 23, 1068\u20131079 (2017).","journal-title":"Clin. Cancer Res."},{"key":"4700_CR3","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.2147\/OTT.S249822","volume":"13","author":"Q Lu","year":"2020","unstructured":"Lu, Q. et al. Potential new cancer immunotherapy: anti-CD47-SIRP\u03b1 antibodies. Onco. Targets Ther. 13, 9323\u20139331 (2020).","journal-title":"Onco. Targets Ther."},{"key":"4700_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","volume":"14","author":"Z Jiang","year":"2021","unstructured":"Jiang, Z. et al. Targeting CD47 for cancer immunotherapy. J. Hematol. Oncol. 14, 180 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"4700_CR5","doi-asserted-by":"publisher","first-page":"2006220","DOI":"10.1002\/adfm.202006220","volume":"31","author":"X Zhou","year":"2021","unstructured":"Zhou, X., Liu, X. & Huang, L. Macrophage-mediated tumor cell phagocytosis: opportunity for nanomedicine intervention. Adv. Funct. Mater. 31, 2006220 (2021).","journal-title":"Adv. Funct. Mater."},{"key":"4700_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct. Target Ther. 8, 104 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"4700_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.21037\/tcr.2018.05.31","volume":"7","author":"H-J Zhao","year":"2018","unstructured":"Zhao, H.-J. et al. Prognostic significance of CD47 in human malignancies: a systematic review and meta-analysis. Transl. Cancer Res. 7, 609\u2013621 (2018).","journal-title":"Transl. Cancer Res."},{"key":"4700_CR8","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00262-020-02806-2","volume":"70","author":"M Shi","year":"2021","unstructured":"Shi, M. et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunol. Immunother. 70, 1831\u20131840 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"4700_CR9","volume":"8","author":"Y Ye","year":"2025","unstructured":"Ye, Y. et al. Survival and clinicopathological significance of CD47 in human solid tumors: an updated systematic reviews and meta-analysis. Cancer Rep. 8, e70296 (2025).","journal-title":"Cancer Rep."},{"key":"4700_CR10","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cam4.478","volume":"4","author":"K Yoshida","year":"2015","unstructured":"Yoshida, K. et al. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 4, 1322\u20131333 (2015).","journal-title":"Cancer Med."},{"key":"4700_CR11","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 379, 1711\u20131721 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4700_CR12","doi-asserted-by":"publisher","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu, J. et al. Pre-clinical development of a humanized anti-cd47 antibody with anti-cancer therapeutic potential. PLoS ONE 10, e0137345 (2015).","journal-title":"PLoS ONE"},{"key":"4700_CR13","doi-asserted-by":"publisher","first-page":"e0201832","DOI":"10.1371\/journal.pone.0201832","volume":"13","author":"SE Kauder","year":"2018","unstructured":"Kauder, S. E. et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE 13, e0201832 (2018).","journal-title":"PLoS ONE"},{"key":"4700_CR14","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","volume":"41","author":"JC Osorio","year":"2023","unstructured":"Osorio, J. C., Smith, P., Knorr, D. A. & Ravetch, J. V. The antitumor activities of anti-CD47 antibodies require Fc-Fc\u03b3R interactions. Cancer Cell 41, 2051\u20132065.e6 (2023).","journal-title":"Cancer Cell"},{"key":"4700_CR15","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","volume":"22","author":"NJ Lakhani","year":"2021","unstructured":"Lakhani, N. J. et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 22, 1740\u20131751 (2021).","journal-title":"Lancet Oncol."},{"key":"4700_CR16","first-page":"A530","volume":"9","author":"KW Lee","year":"2021","unstructured":"Lee, K. W. et al. Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric\/gastroesophageal cancer (GC); ASPEN-01. J. Immunother. Cancer 9, A530 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"4700_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang, Y.-J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"4700_CR18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian, Y. Y. et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomized placebo-controlled trial. Lancet 402, 2197\u20132208 (2023).","journal-title":"Lancet"},{"key":"4700_CR19","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3390\/cancers16071336","volume":"16","author":"MK Scheck","year":"2024","unstructured":"Scheck, M. K., Hofheinz, R. D. & Lorenzen, S. HER2-positive gastric cancer and antibody treatment: state of the art and future developments. Cancers 16, 1336 (2024).","journal-title":"Cancers"},{"key":"4700_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"24","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N. Engl. J. Med. 24, 336\u2013348 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4700_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki, H. et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur. J. Cancer 105, 41\u201349 (2018).","journal-title":"Eur. J. Cancer"},{"key":"4700_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/614619","volume":"2013","author":"PA Oldenborg","year":"2013","unstructured":"Oldenborg, P. A. CD47: a cell surface glycoprotein which regulates multiple functions of hematopoietic cells in health and disease. ISRN Hematol. 2013, 614619 (2013).","journal-title":"ISRN Hematol"},{"key":"4700_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699\u2013713 (2010).","journal-title":"Cell"},{"key":"4700_CR24","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2024-210894","volume":"144","author":"LDS Johnson","year":"2024","unstructured":"Johnson, L. D. S. & Zhang, Y. Impact of mutational landscape and CD47 levels in the magrolimab + azacitidine vs placebo + azacitidine trial in patients with untreated higher risk myelodysplastic syndrome. Blood 144, 4604 (2024).","journal-title":"Blood"},{"key":"4700_CR25","first-page":"A212","volume":"12","author":"N Van Buuren","year":"2024","unstructured":"Van Buuren, N. et al. 184 Biomarker analysis of magrolimab plus docetaxel in patients with 2L+ mNSCLC from ELEVATE-Lung and UC, a phase 2 multicohort study. J. Immuno.Ther. Cancer 12, A212 (2024).","journal-title":"J. Immuno.Ther. Cancer"},{"key":"4700_CR26","doi-asserted-by":"publisher","first-page":"111478","DOI":"10.1016\/j.isci.2024.111478","volume":"27","author":"C Chen","year":"2024","unstructured":"Chen, C., Lu, F., Huang, H. & Pan, Y. Translating CD47-targeted therapy in gastrointestinal cancers: Insights from preclinical to clinical studies. iScience 27, 111478 (2024).","journal-title":"iScience"},{"key":"4700_CR27","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"key":"4700_CR28","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3324\/haematol.2024.286208","volume":"110","author":"TM Kim","year":"2025","unstructured":"Kim, T. M. et al. Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study. Haematologica 110, 2102\u20132112 (2025).","journal-title":"Haematologica"},{"key":"4700_CR29","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"27","author":"SM Ansell","year":"2021","unstructured":"Ansell, S. M. et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 27, 2190\u20132199 (2021).","journal-title":"Clin. Cancer Res."},{"key":"4700_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","volume":"31","author":"SJ Pocock","year":"1975","unstructured":"Pocock, S. J. & Simon, R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31, 103\u2013115 (1975).","journal-title":"Biometrics"},{"key":"4700_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley, A. N. et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 35, 446\u2013464 (2017).","journal-title":"J. Clin. Oncol."},{"key":"4700_CR32","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/sim.3123","volume":"27","author":"T Koyama","year":"2008","unstructured":"Koyama, T. & Chen, H. Proper inference from Simon\u2019s two-stage designs. Statist. Med. 27, 3145\u20133154 (2008).","journal-title":"Statist. Med."},{"key":"4700_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2967\/jnumed.120.251520","volume":"62","author":"MC Polley","year":"2021","unstructured":"Polley, M. C. & Dignam, J. J. Statistical considerations in the evaluation of continuous biomarkers. J. Nucl. Med. 62, 605\u2013611 (2021).","journal-title":"J. Nucl. Med."},{"key":"4700_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41379-020-00710-9","volume":"34","author":"K Emancipator","year":"2021","unstructured":"Emancipator, K. et al. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod. Pathol. 34, 532\u2013541 (2021).","journal-title":"Mod. Pathol."},{"key":"4700_CR35","doi-asserted-by":"crossref","unstructured":"Hui, J. & Guo, W. Optimal biomarker cutoff identification and validation. In Statistics in Biosciences Vol. 14, 352\u2013362 (Springer, 2022).","DOI":"10.1007\/s12561-022-09340-y"},{"key":"4700_CR36","doi-asserted-by":"publisher","first-page":"A332","DOI":"10.1200\/JCO.2025.43.4_suppl.332","volume":"43","author":"K Shitara","year":"2025","unstructured":"Shitara, K. et al. Final analysis of the randomized phase 2 part of the ASPEN-06 study: a phase 2\/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric\/gastroesophageal cancer (GC). J. Clin. Oncol. 43, A332 (2025).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04700-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:02:13Z","timestamp":1790240533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04700-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":36,"alternative-id":["4700"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04700-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.S. reports receiving personal fees for consulting and advisory roles from Bristol-Myers Squibb, Takeda, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Merck Pharmaceutical, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology, Bayer, GlaxoSmithKline K.K., HEALIOS K.K., Moderna and Arcus Biosciences; receiving honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas and AstraZeneca; and receiving research funding (all to institution) from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Amgen, Eisai, PRA Health Sciences, Syneos Health, AstraZeneca, PPD-SNBL K.K. and TORAY. Z.W. reports consulting for Abbvie, Amgen, Alligator, AstraZeneca, Daiichi, Merck, BMS, Novartis and Revolution Medicine. J.T. reports personal financial interest in the form of scientific consultancy roles for Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Carina Biotech, Cartography Biosciences, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, Ipsen Innovation SAS, Johnson & Johnson\/Janssen, Kayak Therapeutics, Larkspur Biosciences, Lilly, Marengo Therapeutics, Menarini, Merus, MSD, Novartis, One-carbon Therapeutics, Ono Pharma USA, Peptomyc, Pfizer, Pierre Fabre, Quantro Therapeutics, Scandion Oncology, Scorpion Therapeutics, Servier, Sotio Biotech, Syntelios AG, Taiho, Takeda Oncology, Theriva Biologics and Tolremo Therapeutics; and stocks from Adualys Therapeutics, Alentis Therapeutics, Oniria Therapeutics, 1TRIALSP and Pangaea Oncology. E.V.C. reports participation in advisory boards for Abbvie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas, AstraZeneca, Bayer, Beigene, Bexon Clinical, Biontech, Boehringer Ingelheim, Bristol-Myers Squibb, Cantargia, Daiichi, Debiopharma, Elmedix, Eisai, Fosum, Galapagos, GSK, Ipsen, Iteos, Lilly, Merck Sharp & Dohme, Merck KGaA, Microbial Machines, Mirati, Novartis, Nordic, Novocure, Pierre Fabre, Pfizer, Sanofi, Seattle Genetics, Servier, Simcere, Takeda, Taiho and Trishula. C.C. reports receiving personal fees for consulting and advisory roles from MSD Oncology, Merck Serono, Daiichi Sankyo, AstraZeneca, Bristol-Myers Squibb, Jazz Pharmaceuticals, Gilead, Astellas, Pierre Fabre, Servier, and Amgen; and receiving honoraria from Servier, Amgen, Merck Serono, Bristol-Myers Squibb, Daiichi Sankyo, Merck Sharp & Dohme, Merck Serono and AstraZeneca. C.D.L.F. reports receiving personal fees for consulting and advisory roles from Agenus, Amgen, Astellas, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichi Sankyo, Eisai, Gilead, Ipsen, Jazz Pharmaceuticals, Lilly, Merck, MSD, Natera, Pierre Fabre Oncologie, Roche, Servier and Summit Therapeutics. J.L. reports nonfinancial interests from the following roles: steering committee member for AstraZeneca and Seattle Genetics; Principal Investigator for AstraZeneca, BMS, Daiichi Sankyo, Leaptherapeutics and Merck MSD; Project Lead for Genome and Company, Oncxerna and Samsung Bioepis; advisory role for Mirati Therapeutics; AP council member for ASCO; and KSMO member. P.F., A.F., J.P., A.C.T., C.M. and S.R. were employed by ALX Oncology at the time of the study and report stock and other ownership interests at ALX Oncology. D.B. was consulting with ALX Oncology, Elevation Oncology, Avidicure, Stork Therapeutics, Firefly Bio and Boxer Capital; is employed part-time by Intelligencia; and reports stock and other ownership interests in ALX Oncology, Enliven Therapeutics and Intelligencia. J.P. and S.R. were on the board of directors at ALX Oncology at the time of the study. J.P. also reports a leadership or fiduciary role at Tallac Therapeutics. K.-W.L. reports research support paid to his institution from ALX Oncology, AstraZeneca, Ono Pharmaceutical, Merck Sharp & Dohme, Merck KGaA, Roche, Pfizer, BeiGene, Leap Therapeutics, Zymeworks, Astellas, MacroGenics, Amgen, Seagen, Bolt Therapeutics, Trishula Therapeutics, Oncologie, Pharmacyclics, MedPacto, Green Cross Corp, ABL Bio, Y-Biologics, Daiichi Sankyo, Taiho Pharmaceutical, InventisBio, Elevar Therapeutics, MetaFines, Idience, Genome & Company and Exelixis; personal fees\/honoraria from Ono Pharmaceutical, Boryung, Daiichi Sankyo, Astellas and Sanofi-Aventis; and participation on a data Ssafety monitoring board or advisory board for ALX Oncology and MetaFines. S.Y.R. and Y.-K.K. declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}